303 related articles for article (PubMed ID: 12201832)
1. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
3. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
[TBL] [Abstract][Full Text] [Related]
6. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
11. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
[TBL] [Abstract][Full Text] [Related]
12. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys.
Wilson ME
J Clin Endocrinol Metab; 2000 Apr; 85(4):1557-62. PubMed ID: 10770197
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
15. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
16. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover.
Gürlek A; Gedik O
J Endocrinol Invest; 2001 Jun; 24(6):408-14. PubMed ID: 11434664
[TBL] [Abstract][Full Text] [Related]
17. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins.
Scacchi M; Danesi L; Cattaneo A; Sciortino G; Radin R; Ambrogio AG; Vitale G; D'Angelo E; Mirra N; Zanaboni L; Arvigo M; Boschetti M; Ferone D; Marzullo P; Baldini M; Cassinerio E; Cappellini MD; Persani L; Cavagnini F
Endocrine; 2016 Aug; 53(2):551-7. PubMed ID: 26825070
[TBL] [Abstract][Full Text] [Related]
19. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
20. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
